anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients already assessed at GHICL's Valvulopathy Centre from 2011 to October 2023 will be identified retrospectively, by queries based on keywords and/or diagnostic codes in echocardiography interpretation software (Viewpoint/EchoPAC, ISCV). GHICL's Medical Information Department will also be involved.
PURPOSE: To obtain a perfumery composition for fragrance goods for enjoying the fragrance, having excellent durability of fragrance and exhibiting skin- treatment effect by adding a water-soluble polymer to a water base absolutely free from ethyl alcohol. CONSTITUTION: This liquid or jelly perfumery composition essentially free from ethyl alcohol is produced by adding 0.001-10wt.% of a water-soluble polymer to a system containing 0.5-30wt.% of a perfumery component and 50-99wt.% of water. The water-soluble polymer is e.g. corn starch, xanthan gum or hydroxypropyl cellulose. The system may be further incorporated with 0.1-30wt.% of a humectant component (e.g. glycerol or propylene glycol) and 0.1-30wt.% of an oily component (e.g. avocado oil or squalane). The perfumery composition has lasting fragrance and excellent feeling to the skin and skin- improving effect. Even a person sensitive to alcohol can safely use the composition because the composition is absolutely free from alcohol.
Human restrictin proteins and nucleic acid sequences encoding them are provided. Antibodies which recognize human restrictin in human brain are disclosed. In the human brain, restrictin occurs as two major polypeptides of 180 and 160 kD located in fiber tracts. These polypeptides are similar to those seen in rat brain. Surprisingly, restrictin has also been found in the peripheral nerves of rats and humans. The antibodies also detect a 170 kD polypeptide in MATRIGELTM, an extracellular matrix product of rat EHS sarcoma cells widely used as a tissue culture substrate. Monoclonal antibodies to human restrictin and assays using the human restrictin protein, antibodies and DNA sequences are also provided.
Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
The invention discloses angelica sinensis honey liquor which is prepared through conventional technologies from following components, by weight, 40 parts of angelica sinensis, 60 parts of honey, 15 parts of American ginseng, 10 parts of fructus lycii, 15 parts of poria cocos, 10 parts of semen cassiae, 3 parts of bezoar from monkey and 1000 parts of liquor. The components, except the liquor, are placed in a container with addition of the liquor. The container is sealed and the components are soaked in the liquor for 15 days. Filtration is carried out to remove residues to obtain the angelica sinensis honey liquor. The angelica sinensis honey liquor has effects of nourishing blood and retaining youthful looks and is mainly used for treating skin pigmentation, facial acne, dryness and sparsity in hair and the like. The angelica sinensis honey liquor has effects of nourishing and fortifying body, caring health and beautifying face, and delaying senescence. The angelica sinensis honey liquor is taken orally with a dosage being 15ml by two times per day.
PURPOSE: To provide a new phospholipid antifungal agent containing effective amts. of a specified compd. and its alkali metal salt and having a wide antifungal spectrum and low toxicity.  
     CONSTITUTION: The compd. of the formula is obtd. in the following processes. 1-Stearoyl(or palmitoyl)-2-linoleoyl-3-glycerophosphatidyl-D-myoinositol is mixed with a lyase having phospholipase A 1  activity under condition of pH6 to 7 to obtain a lisophosphatidyl inositol containing 2-linoleoyl-3-glycerophosphatidyl- D-myoinositol. Then the product is subjected to chromatography in a C-18 reverse phase column to collect 2-linoleoyl-3-glycerophosphatidyl-D-myoinositol, which is then brought into contact with a buffer soln. such as TAPS [N- tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid] under condition of pH8.5 to cause intramolecular transacylation to obtain the compd. of the formula. The obtd. compd. by 1 wt.% is deposited on a pharmaceutically acceptable carrier to obtain the objective antifungal agent. 
     COPYRIGHT: (C)1993,JPO
Repetition increases belief in information, a phenomenon known as the illusory truth effect. In laboratory experiments, the illusory truth effect has often been examined using general trivia statements as stimuli, but repetition also increases belief in misinformation, such as fake news headlines and conspiracy beliefs. Repetition even increases belief in claims that are implausible or that contradict prior knowledge. Repetition also has broader impacts beyond belief, such as increasing sharing intentions of news headlines and decreasing how unethical an act is perceived to be. Although the illusory truth effect is robust, some interventions reduce its magnitude, including instruction to focus on accuracy and awareness of the illusory truth effect. These strategies may be effective for reducing belief in misinformation.
Targeting ferroptosis for cancer therapy has slowed because of an incomplete understanding of ferroptosis mechanisms under specific pathological contexts such as tumorigenesis and cancer treatment. Here, we identify TRPML1-mediated lysosomal exocytosis as a potential anti-ferroptotic process through genome-wide CRISPR-Cas9 activation and kinase inhibitor library screening. AKT directly phosphorylated TRPML1 at Ser343 and inhibited K552 ubiquitination and proteasome degradation of TRPML1, thereby promoting TRPML1 binding to ARL8B to trigger lysosomal exocytosis. This boosted ferroptosis defense of AKT-hyperactivated cancer cells by reducing intracellular ferrous iron and enhancing membrane repair. Correlation analysis and functional analysis revealed that TRPML1-mediated ferroptosis resistance is a previously unrecognized feature of AKT-hyperactivated cancers and is necessary for AKT-driven tumorigenesis and cancer therapeutic resistance. TRPML1 inactivation or blockade of the interaction between TRPML1 and ARL8B inhibited AKT-driven tumorigenesis and cancer therapeutic resistance in vitro and in vivo by promoting ferroptosis. A synthetic peptide targeting TRPML1 inhibited AKT-driven tumorigenesis and enhanced the sensitivity of AKT-hyperactivated tumors to ferroptosis inducers, radiotherapy, and immunotherapy by boosting ferroptosis in vivo. Together, our findings identified TRPML1 as a therapeutic target in AKT-hyperactivated cancer.
A 59-year-old Japanese woman presented with hyperferritinemia. We decided against iron removal treatment because there were no symptoms or signs of iron-induced organ damage. A follow-up study revealed a gradual increase in transferrin saturation. The patient underwent a second examination at 66 years old. A liver biopsy showed substantial iron deposits in hepatocytes and Kupffer cells but no inflammation or fibrosis. Serum hepcidin-25 levels were highly parallel with hyperferritinemia. A genetic analysis revealed a G80S mutation in SLC40A1. These features are compatible with those of ferroportin disease. The patient remained asymptomatic at 70 years old, suggesting that the iron-loading condition may have been benign.
Disclosed herein are systems and methods for determining and tracking a goal associated with user's health. The method determines a goal of a user. The method generates a goal file based on the goal and generates a social networking campaign file comprising data from the goal file and predetermined criteria for achieving the goal. The method receives social contacts of the user and determines social contacts to invite to the social networking campaign. The method transmits a request to each determined social contact to join the social networking campaign. The method updates the social networking campaign file with data representing the social contacts. The method monitors goal progress data, determines an extent to which the goal progress data satisfies predetermined criteria in the goal file, and generates instructions to update a goal progress score accordingly.
PURPOSE: A composition containing a compound for enhancing cell growth is provided to enhance growth of brain cells, nerve cells, cardiac cells, and stem cells and to treat diseases which are needed to cell proliferation. CONSTITUTION: A composition for enhancing cell growth contains a compound of chemical formula 1. A formulation for enhancing cell growth contains the compound of chemical formula 1. The formulation is used in the form of lipid nanoparticle, polymer nanoparticle or polymer gel. The lipid nanoparticle contains positive charge lipid, neutral lipid or negative charge lipid. The lipid nanoparticle additionally contains surfactant. The polymer nanoparticle or polymer gel contains natural polymer or synthetic polymer. The formulation further contains cell target ligand.
The invention provides a double-strand polynucleotide-epsilon-polylysine-sulfuric acid glycan compound with an immune regulating function and a preparing and using method thereof. The invention further provides an immunogen composition with functions of triggering and enhancing immunoreaction and changing immunoreaction types. The immunogen composition contains the double-strand polynucleotide-epsilon-polylysine-sulfuric acid glycan compound and an antigen. The compound is formed by compounding double-strand polynucleotide and anion sulfuric acid glycan with cation epsilon-polylysine and metal cation. The compound has immune-regulating pharmacological activity. The preparing technology of the compound is simple. The compound has good water solubility and a function of resisting biological enzyme degradation. The immunogen composition can trigger and enhance the immunoreaction and change the immunoreaction types.
PURPOSE:To obtain a preventive and treating agent of ischemia re-perfusion disorder effective for preventing and treating myocardial infarction and arrhythmia after natural pantency caused by cardiac coronary occlusion, comprising a specific sulfonanilide compound and a salt as active ingredients. CONSTITUTION:A preventive and treating agent for ischemia re-perfusion disorder comprising a compound shown by formula I (R<2> is lower alkyl; R<2> is lower alkanoyl, carbamoyl, cyano, etc.; R<3> is H or R<2> and R<3> together with C form ring shown by formula II; R<4> and R<5> are H or halogen; X is O or S) and a salt (e.g. lithium salt or sodium salt) as active ingredients. The compound shown by formula I is effectively used with an immunosuppressive agent in organ transplantation. A daily dose of the compound shown by formula I is 0.5-1,000mg, preferably 1-500mg usually by oral administration.
Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion.
The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
The invention provides a granisetron composition for injection and relates to the technical field of medicaments and medicament manufacturing. The main medicaments of the composition are granisetron and melatonin, wherein the melatonin comprises a quick release part and a slow release part contained in cyclodextrin. The granisetron composition for injection provided by the invention can be used for improving the treatment effect of the granisetron, avoiding instability, quick distribution and elimination and the like of MT ((Metal Thionein) caused by oral absorption, reducing the first-pass effect of the MT and reducing the dosage of the granisetron. The medicament administration design combining the quick release with the slow release satisfies physiological secretion characteristics of the MT, can be used for solving the problem that the half-life period of the MT is short, increasing the biological utilization rate of the granisetron composition, and achieving the synergism of the granisetron for treating CINV (Chemotherapy Induced Nausea And Vomiting). The quick release part and the slow release part are combined, so that not only can the CINV be treated, but also the treatment effect of the granisetron on the CINV can be improved, and therefore, the treatment course is shortened, the dosage of the granisetron is reduced, the side effect of the granisetron is lowered, and the body immunity can be improved. A certain concentration of melatonin is kept in the blood of the human body, so that the stress response of the organisms can be effectively lowered for facilitating the treatment of the CINV.
Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
INTRODUCTION: The treatment outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) have improved with various tyrosine kinase inhibitors (TKIs) and bispecific T-cell engagers. Although allogeneic stem cell transplantation (allo-SCT) is the standard treatment for young patients with Ph+ALL, its role remains debatable in the era of TKIs and blinatumomab.
AREAS COVERED: There are some issues regarding Ph+ALL. First, do young patients require intensive chemotherapy (IC) in the era of multitarget agents? Second, which TKI is preferred for frontline therapy? Third, should allo-SCT be performed in patients achieving complete remission with ponatinib and IC? Fourth, can chemo-free treatment lead to a cure without allo-SCT? We searched relevant literature from the last 30 years on PubMed; reviewed the role of chemo-free therapies and combinations of ponatinib and IC; and assessed the necessity of allo-SCT in young patients with Ph+ALL.
EXPERT OPINION: Allo-SCT may not be needed, even in young patients with Ph+ALL treated with ponatinib-based IC or combined ponatinib and blinatumomab as frontline therapy. When adopting a ponatinib-based chemo-minimized regimen for induction, allo-SCT is needed with posttransplant ponatinib maintenance. Continuous exposure to ponatinib at pre- or post-transplant is regarded as one of the most important factor for the success of treatment.
OBJECTIVE: More than one-third of pediatric patients who undergo resection of intradural spine lesions develop progressive postoperative deformity, with as many as half of these patients subsequently requiring surgical fusion. Intradural spinal procedures with simultaneous instrumented fusion in children, however, are infrequently performed. Moreover, the rationale for patient selection, outcomes, and safety of this single-stage surgery in children has not been systematically investigated. In this study, the authors review the practice of simultaneous intradural spinal resection and instrumented fusion in pediatric patients and provide two representative case examples from their institution.
METHODS: The authors searched the PubMed and Embase databases and performed a systematic review following the PRISMA protocol. Original articles of pediatric patients (age ≤ 18 years) who underwent intradural spine surgery, regardless of pathology, with concomitant instrumented fusion and reported outcomes were included. An institutional database of all spinal operations with instrumented fusion performed in patients aged ≤ 18 years over a 3-year period was screened to identify those who underwent intradural spine surgery with concomitant fusion.
RESULTS: Nine patients (median age 12 years) from 6 studies who underwent intradural lesion resection and concomitant fusion met inclusion criteria. Among all 11 patients included, primary rationales for concomitant fusion were extensive bone removal (i.e., corpectomy or total facetectomy, 73%), concerns for deformity in the setting of multilevel laminectomy/laminoplasty (18%), and severe baseline deformity (9%). The most represented pathology was neurenteric cyst (55%) followed by schwannoma (18%). Myxopapillary ependymoma, granular cell tumor, and pilocytic astrocytoma each were seen in 1 case. Seven patients (64%) underwent an anterior-approach corpectomy, tumor resection, and fusion, while the remaining 4 patients (36%) underwent a posterior approach. All patients with at least 1 year of follow-up cases achieved bony fusion. CSF leak and new-onset neurological deficit each occurred in 9% (1/11).
CONCLUSIONS: The rationales for performing single-stage intradural resection and fusion in pediatric patients in studies to date include the presence of severe baseline deformity, large extent of bone resection, and multilevel laminectomy/laminoplasty across cervicothoracic or thoracolumbar junctions. As current literature involving this cohort is limited, more data are needed to determine when concomitant fusion in intradural resections is appropriate in pediatric patients and whether its routine implementation is safe or beneficial.
Recent advances in the treatment of plasma cell disorders (PCDs) have provided a wealth of therapy alternatives and improved overall survival tremendously. Various types of PCDs are associated with kidney injury and end-stage kidney disease in a considerable number of patients. Kidney transplantation (KTx) is the best option for renal replacement therapy in select patients in terms of both quality of life parameters and overall survival. Even with modern therapies, all PCDs carry the risk of hematologic progression, whereas histologic recurrence and graft loss are other prevailing concerns in these patients. The risk of mortality is also higher in some of these disorders compared with KTx recipients who suffer from other causes of kidney disease. Unlike solid cancers, there is no well-defined "waiting time" after hematologic remission before proceeding to KTx. Thus, clinicians are usually reluctant to recommend KTx to patients who develop end-stage kidney disease due to PCDs. This review aims to provide the current evidence on KTx outcomes in patients with monoclonal gammopathy of renal significance and multiple myeloma. Although immunoglobulin light chain amyloidosis is a monoclonal gammopathy of renal significance subtype, KTx outcomes in this group are mentioned in another chapter of this issue.
PURPOSE:To obtain the subject inhibitor, containing birch tree tar (reetifield oil or birch tar oil) as an active ingredient, having testosterone 5alpha-reductase inhibitory action, capable of inhibiting common acne and sebum secretory ability and effectively used in prescriptions, etc., for medicines and cosmetics useful for seborrheic alopecia, eczema, etc. CONSTITUTION:A testosterone 5alpha-reductase inhibitor containing birch tree tar (Reetifield oil or Birch Tar Oil) obtained from a tree of the family Betulaceae, Betula platyphylla Sekatchev var. japonica, Betula ermani Cham. or Betula globispica Shirai by a dry distillation method as an active ingredient. In use, the inhibitor is employed by blending thereof in a dosage form, e.g. embrocation to common acne, seborrheic dermatopathy or alopecia for external use, or oral administration, etc.
Bread wheat (Triticum aestivum) is a globally dominant crop and major source of calories and proteins for the human diet. Compared with its wild ancestors, modern bread wheat shows lower genetic diversity, caused by polyploidisation, domestication and breeding bottlenecks1,2. Wild wheat relatives represent genetic reservoirs, and harbour diversity and beneficial alleles that have not been incorporated into bread wheat. Here we establish and analyse extensive genome resources for Tausch's goatgrass (Aegilops tauschii), the donor of the bread wheat D genome. Our analysis of 46 Ae. tauschii genomes enabled us to clone a disease resistance gene and perform haplotype analysis across a complex disease resistance locus, allowing us to discern alleles from paralogous gene copies. We also reveal the complex genetic composition and history of the bread wheat D genome, which involves contributions from genetically and geographically discrete Ae. tauschii subpopulations. Together, our results reveal the complex history of the bread wheat D genome and demonstrate the potential of wild relatives in crop improvement.
Acquired brain lesions such as stroke often result in the most common disabling neurological damages. Up to 42% of stroke patients suffer serious language deficits and patients are frequently left with chronic disabilities which adversely impact their quality of life. One of the main challenges in aphasia rehabilitation includes long-term effects. After a certain time (i.e., 3-6mo, chronic phase), the frequency of therapy will decrease or stop, even if the patient has not always reached the expected or desired level of recovery. After this, a body of evidence suggests that the person with aphasia might decrease the use of verbal language given the negative reinforcement when trying to use the deteriorated function and failing to achieve a successful communication. This might lead to relying on other forms of communication (e.g., gestures) and to a vicious cycle of deterioration of verbal skills known as Learned Non-Use principle. Together with the pandemic socioeconomic situation and limited resources at healthcare facilities, this calls for the need of effective and efficient interventions that can be deployed at the house of the patients, in the form of auto-administered therapy. Despite the limited exploration of portable technologies in aphasia recovery, their use has been extensive and successful in other domains such as motor rehabilitation. Importantly, patients with aphasia report that the number 1 topic they would like to know more about is how to keep recovering after therapy ends.

Following recent evidence on experience-dependent plasticity mechanisms for successful stroke recovery and well-established theory-grounded interventions, such as ILAT, the present study aims to study the usability and improvement potential of a mobile-based aphasia rehabilitation app for stroke patients, used at home. A previous collaboration between both centers (SPECS lab and Hospital Joan XIII) used a computer-based setup. In this study by Grechuta et al. (2019), the Rehabilitation Gaming System for aphasia (RGSa) shows positive significant results on language (P= 0.001) and communication (P\<0.05) compared to conventional therapy in the long term (16 weeks). This study will assess the usability, risks, and clinical outcome of the same principles applied to a mobile application that is prescribed to be used at home for two twenty-minutes session per day during two weeks.